Tagged with oncology,

USA Astellas has steadily developed its immuno-oncology (IO) pipeline via both organic and inorganic means in recent years, with its early-phase IO projects now overseen by industry veteran Peter Sandor, the company’s SVP and IO Primary Focus Lead. Sandor explains the variety of exciting IO approaches in development at Astellas, how…

UAE MSD GCC’s new memorandum of understanding (MoU) with The Department of Health Abu Dhabi (DoH) aims to advance research into breast and lung cancer. The deal, signed at the BIO International Convention 2023, marks the continuation of a long-term collaboration between the two entities.   Present at the signing were…

USA Although clinical trial diversity remains high on the agendas of industry sponsors, there is still a long road to travel towards more equitable and representative research – and ultimately safer and more effective medicines. On this theme, writing in the June 2023 edition of the DIA Global Forum magazine, Jorge…

UAE Amr Seif outlines Astellas’ progress into becoming a focused oncology speciality player in the Middle East and Africa, in line with the company’s global Corporate Strategic Plan 2021 (CSP2021). He also touches on key market trends in MEA, including regulatory developments, the rise of private insurance, and the growing importance…

Belgium PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last conversation in 2020, and his hopes for establishing new alliances with manufacturers and Big Pharma players moving forward.   Our…

Belgium Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach to oncology with a focus on hard-to-treat cancers, as well as its focus on patient centricity   In oncology, we…

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

Egypt AbbVie’s GM for Egypt & Levant, Ali Sleiman, explains the factors behind the stellar growth that has made the cluster one of the company’s fastest-growing global markets in 2021. He also discusses the favourable environment created by Egypt’s healthcare reforms and how they have quickened regulatory approvals and access, leading…

France French mid-cap Servier has launched a new visual identity and logo and announced an ambitious 2030 growth plan with an increased focus on hard-to-treat cancers.   Servier, which is governed by a foundation, brought in EUR 4.7 billion in the 2020/21 period according to the firm’s latest annual report, and…

Italy Giuseppe Maduri, Chairman, Managing Director, General Manager Italy, Greece, Cyprus, Malta at Astellas Pharma explains the Japanese company’s focus on unmet needs and how Italy, one of its top European markets, is working to ovecome market access challenges.  Greater anticipation would allow patients’ faster access to innovation but requires a…

Italy Paivi Kerkola, Country Manager, Managing Director and President of Pfizer Italy, speaks about the peculiarities of the Italian market from a northern European perspective, her priorities, and the impact of the COVID-19 pandemic and how it not only put Pfizer in the spotlight but also triggered an unprecedented dialogue between…

Global Swiss pharma giant, Roche, has announced a change in leadership that will see Severin Schwan replaced by diagnostics division head, Thomas Schinecker, after a 14-year stint as CEO. Schinecker, who became a contender for the role by leading the company’s efforts in developing a COVID-19 test kit, growing sales by…